# Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC)

> **NCT06654336** · PHASE2 · RECRUITING · sponsor: **Ontario Clinical Oncology Group (OCOG)** · enrollment: 162 (estimated)

## Conditions studied

- Prostate Adenocarcinoma
- Castration Sensitive Prostate Cancer

## Interventions

- **RADIATION:** Recurrence-directed therapy (RDT)
- **DRUG:** ELIGARD 22.5mg

## Key facts

- **NCT ID:** NCT06654336
- **Lead sponsor:** Ontario Clinical Oncology Group (OCOG)
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-30
- **Primary completion:** 2031-04
- **Final completion:** 2031-06
- **Target enrollment:** 162 (ESTIMATED)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06654336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06654336, "Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC)". Retrieved via AI Analytics 2026-08-23 from https://api.ai-analytics.org/clinical/NCT06654336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*